Sanuwave’s Q2 Results: A Mixed Picture for the Ultrasound Wound‑Care Company

Sanuwave Health, a maker of ultrasound‑based wound‑care devices, announced that it expects to bring in $9.6 million to $9.8 million in revenue during the second quarter of 2026—above the upper limit of its earlier forecast of $8.5 million to $9.5 million.

• Earnings slipped roughly 3%–5% compared with the $10.1 million earned in the same period last year.
• CEO Morgan Frank noted that revenue for the quarter surpassed the top of the company’s June guidance and that overall performance was largely in line with expectations.

Challenges & Strategies

• Capital Equipment Sales: Facing pressure as customers struggle to pay and newer used UltraMIST machines are more readily available.
• Response: Helping new customers qualify, train, and service their systems; offering trade‑in options for certified pre‑owned units with manufacturer warranties.

Bright Spot

• Consumable Applicator Sales: A surge hit record levels in both units sold and revenue.

Business Model & Product

Sanuwave’s model centers on directed energy technology that stimulates tissue repair through non‑invasive ultrasound or shockwaves. Its flagship product, the FDA‑cleared UltraMIST system, treats a range of acute and chronic wounds.

• The company operates as a single‑segment business focused on designing and selling medical devices, with most revenue from the United States.
• Quarterly sales are a clear short‑term barometer of market acceptance for its single product line.

Analyst Outlook

• Mixed feelings: growth potential noted, but current momentum is weak.
• A stronger revenue trend could help the stock recover recent losses, especially if it regains key moving‑average support.

Stock Performance

At the time of reporting, Sanuwave shares were down about 4.44%, trading around $6.36.